Compare FLOC & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLOC | CMPX |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | 1281 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.8M | 927.5M |
| IPO Year | N/A | 2020 |
| Metric | FLOC | CMPX |
|---|---|---|
| Price | $27.21 | $2.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $28.50 | $14.57 |
| AVG Volume (30 Days) | 588.4K | ★ 12.1M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.92 | N/A |
| Revenue Next Year | $8.59 | $934.41 |
| P/E Ratio | $16.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.03 | $1.61 |
| 52 Week High | $28.26 | $6.88 |
| Indicator | FLOC | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 64.93 | 34.36 |
| Support Level | $14.96 | $1.61 |
| Resistance Level | N/A | $3.54 |
| Average True Range (ATR) | 1.08 | 0.14 |
| MACD | 0.09 | 0.13 |
| Stochastic Oscillator | 81.76 | 78.75 |
Flowco Holdings Inc is a provider of production optimization, artificial lift, emissions management, and monetization solutions for the oil and natural gas industry. Its technologies include high-pressure gas lift (HPGL), conventional gas lift, plunger lift, and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions, which includes rental services, and Natural Gas Technologies, which include service, gas compression parts, and equipment sales. Production Solutions: relates to rentals, sales, and services related to high-pressure gas lift, conventional gas lift, and plunger lift; including other digital solutions and methane abatement technologies, and has maximum revenue. It generates maximum revenue from the United States.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.